



nij barrahûs  
centrum voor vruchtbaarheid

serpha

nij geertgen  
centrum voor vruchtbaarheid

nij linge  
kinderwenscentrum

Legropharma

## FutureLife expands its footprint in the Western Europe through strategic partnership with Nij Group, leading IVF group in the Netherlands

Prague/Elsendorp, 01 November 2021 – FutureLife, one of the European leaders in the field of assisted reproduction, genetics and women's health with forecasted revenues of 180 million EUR in 2021, backed by its shareholders Hartenberg Holding, MD Štěpán Machač, MD Ladislav Zgabur and Mr. Matěj Stejskal, announces the acquisition of Nij Group, the largest private provider of assisted reproduction in Netherlands.

Nij Group consists of three fertility clinics, a fertility pharmacy Serpha, a fertility wholesaler Legropharma, and an educational institution for fertility professionals Nij Science. Most treatments and medication offered by Nij Group are reimbursed by the Dutch health insurers. Nij Group is seen as an industry leader in quality and innovative fertility treatments in the Netherlands. Founded in 2009, Nij Group has currently more than 70 employees and is forecasted to achieve more than 20 million EUR revenues in 2021. There are more than 6.000 patients every year at the Nij Group clinics who look for assistance and the clinics plan to perform more than 6.500 treatment cycles in 2021.

FutureLife is one of the leading European players in reproductive medicine and women's health with presence in 7 European countries: Ireland, United Kingdom, Romania, Finland, Estonia, Czech Republic and Slovakia. Thanks to its clinics and physicians more than 10.000 babies are brought into the world every year. After the acquisition of Nij Group, FutureLife will be present in 8 European countries with 42 clinics providing more than 38 000 treatment cycles annually. FutureLife forecasts its revenues of more than 180 million EUR in 2021, growing constantly over last 7 years.

The transaction is expected to close this week. Current owners will continue in the company as shareholders and dr. Schoonenberg-Nij Geertgen, dr. van den Dool-Nij Linge and dr. Mous-Nij Barrahus stay on as medical director.

Jozef Janov, Founder and Chairman of the Board of FutureLife: "I am thrilled to welcome Nij Group and its team to the FutureLife family. We appreciate great progress the team made in the Netherlands and we are looking forward to support Nij Group in its expansion on the Dutch and German market. Partnership with Nij Group is another important milestone in FutureLife's vision to become the European leader in assisted reproduction."

Matěj Stejskal, CEO and shareholder of FutureLife adds: „During the transaction in the last few months, we understood that both companies, FutureLife and Nij Group share the same vision and principles to provide best in class care for our patients across Europe. For us it is the next important market after our successful entry into Ireland, Finland, Estonia and Romania. FutureLife's approach is based on

# FutureLife

harmonization as we identify and share the best knowledge between the group, while maintaining clinic brands and strong clinical autonomy. We are looking for partners who are able to help us grow the business further and bring excellence into our operations. Nij Group has all of these parameters and exceptional people."

CEO Nij Group Marieke Schoonenberg: "We are happy that Nij Geertgen, Nij Barrahus and Nij Linge will be part of the large European healthcare group. FutureLife is one of the leading healthcare groups in reproductive medicine with 42 IVF clinics in Europe. For us, the partnership is a logical next step in further professionalization and growth. Collaboration with other clinics and experts on European level is from great importance.

We will continue to offer the best possible care to people with a desire to have children. Our clinics will remain accessible and personal but our level of innovation and expertise will increase. This is in line with our mission of being close to the wishes and needs of our clients. We will use the power of the group for the further increase of the chances of pregnancy."

Contact:

JUDr. Matěj Stejskal

Managing Director and Member of the Board of Directors of FutureLife a.s.

[matej.stejskal@futurelife.cz](mailto:matej.stejskal@futurelife.cz)

Tel: +420 226 226 205